18.45 - 20.15
Lehár 2

Who benefits most from an early combination treatment approach in type 2 diabetes?

Evening Session

Matthias Blueher
Welcome and introduction
Matthias Blueher
Clinical inertia and treatment intensification
Helmut Brath
VERIFY results in the context of disease pathogenesis
Juliana Chan
Early combination treatment in practice
Chair-moderated, all speaker Q&A
Matthias Blueher
Closing remarks
Symposium by:
Novartis Pharma AG